Kestra Medical Technologies, Ltd. Form 4 Filings

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director and ten percent owner Jeffrey Lawrence Schwartz reported both an equity award and a tax-related sale of common shares. On September 9, 2026, he acquired 7,217 restricted stock units (RSUs), each convertible into one common share, which vest on September 9, 2027 subject to continued service.

On September 8, 2026, he sold 3,890 common shares at a weighted average price of $25.178 per share, with prices ranging from $24.91 to $25.424, in a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations tied to RSU vesting and settlement. He is also reported as having indirect ownership of 25,172,338 common shares held by Bain Charger Holdings, L.P., where he may be deemed to share voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.

KESTRA MEDICAL TECHNOLOGIES, LTD. (symbol: KMTS) is the issuer of record for a Form 4 filing submitted to the SEC. Kwo Elizabeth reported acquisition or exercise transactions in this Form 4 filing.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that director Elizabeth Kwo received a grant of 7,217 restricted stock units, each representing one common share. After this award, she has 18,126 common shares reported as directly held. The restricted stock units vest on September 9, 2027, subject to her continued service through that date. No Rule 10b5-1 trading plan is reported for this transaction.

KESTRA MEDICAL TECHNOLOGIES, LTD. (symbol: KMTS) is the issuer of record for a Form 4 filing submitted to the SEC.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director Hanley Conor reported two equity transactions: a grant of 7,217 restricted stock units, each convertible into one common share and vesting on September 9, 2027 subject to continued service, and a sale of 5,694 common shares on September 8, 2026 at a weighted average price of $25.2509 per share. The sale was a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) director Kevin C. Reilly reported two equity-related transactions. On September 9, 2026, he received 7,217 restricted stock units, each convertible into one common share, which will vest on September 9, 2027, subject to his continued service. On September 8, 2026, he sold 2,932 common shares in a nondiscretionary, sell-to-cover transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, at a weighted average price of $25.1287 per share.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that director Mary Kay Ladone had two equity-related transactions. On September 9, 2026, she received a grant of 7,217 restricted stock units, each convertible into one common share, scheduled to vest on September 9, 2027, subject to continued service. On September 8, 2026, she sold 3,908 common shares at a weighted average price of $25.1956 per share in a nondiscretionary “sell to cover” transaction to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, with sale prices ranging from $24.91 to $25.43 per share. A prior pro rata distribution had included 17,512 common shares received from West Affum Holdings, L.P., referenced in her holdings.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported that President and Chief Executive Officer Brian Daniel Webster sold 15,000 Common Shares on August 17, 2026 in an open-market transaction at a weighted average price of $27.4787 per share, with individual sale prices ranging from $26.9200 to $27.7700. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. Following this sale, Webster directly holds 460,215 Common Shares.

Kestra Medical Technologies CFO Vaseem Mahboob reported selling a total of 26,287 Common Shares of KMTS on August 7, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted November 6, 2025. The reported sales occurred at weighted average prices of $25.8742 and $26.3300 per share, with detailed price ranges disclosed in the footnotes.

Kestra Medical Technologies Chief Commercial Officer Alfred J. Ford Jr. reported a nondiscretionary sale of 6,275 common shares on 2026-08-04 to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. The shares were sold at a weighted average price of $24.0862, with prices ranging from $23.9000 to $24.5700. Following this tax-related sale, he directly holds 99,564 common shares of Kestra Medical Technologies.

Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported selling 6,995 common shares on August 4, 2026. A sale of 3,080 shares at a weighted average $24.057 was a nondiscretionary sell-to-cover for RSU tax withholding, and a separate 3,915-share sale at $25.1696 occurred under a Rule 10b5-1 trading plan adopted November 6, 2025.

KESTRA MEDICAL TECHNOLOGIES, LTD. executive Traci S. Umberger, General Counsel and Chief Administrative Officer, reported a non-discretionary sale of 3,580 common shares on August 4, 2026, to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. The sale was executed at a weighted average price of $24.0428 per share, with individual prices ranging from $23.8000 to $24.4200.

Following this tax-related sale, Umberger directly holds 195,825 common shares of Kestra Medical Technologies, Ltd.

Kestra Medical Technologies, Ltd.'s President and Chief Executive Officer, Brian Daniel Webster, reported selling 51,900 common shares of KMTS on August 4, 2026, across three sale transactions. Footnotes state these were nondiscretionary sell-to-cover sales to satisfy tax withholding obligations from restricted stock unit vesting, including 48,625 shares at a weighted average price of $24.4692 per share.

Kestra Medical Technologies Chief Business Officer Timothy P. Moran reported nondiscretionary sales of 15,256 common shares to cover tax withholding arising from vested restricted stock units. The shares were sold on July 30, July 31 and August 3, 2026 at weighted average prices of $22.7735, $22.6054 and $23.7611 per share within intraday ranges from $22.15 to $23.98.

Kestra Medical Technologies’ Chief Commercial Officer Alfred J. Ford Jr. reported selling a total of 27,632 Common Shares of KMTS across three transactions on July 30, July 31, and August 3, 2026. These sales, reported as open‑market or private transactions at weighted‑average prices between $22.17 and $24.28 per share, are described as nondiscretionary “sell‑to‑cover” trades made to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units.

Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported sales of 18,188 Common Shares in three transactions on July 30, July 31, and August 3, 2026. The footnotes state these were nondiscretionary sell to cover transactions executed solely to satisfy tax withholding obligations from the vesting and settlement of restricted stock units, with each day’s sales priced at a weighted average within disclosed ranges.

Kestra Medical Technologies, Ltd. insider Traci S. Umberger, a director and officer, reported selling a total of 22229 Common Shares in three open-market or private transactions on July 30, July 31, and August 3, 2026. Footnotes state these were nondiscretionary sell-to-cover sales required to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units, executed at weighted-average prices within ranges from about $22.17 to $24.28 per share.

Kestra Medical Technologies president and CEO Brian Daniel Webster reported sales of 29,822 common shares of KMTS in three transactions on July 30, July 31 and August 3, 2026. The shares were sold at weighted average prices between $22.0577 and $24.1100 solely to cover tax withholding obligations from the vesting and settlement of restricted stock units.

Kestra Medical Technologies, Ltd. executive Timothy P. Moran, Chief Business Officer, reported an acquisition of 39,113 common shares. These shares were earned from a July 17, 2025 grant of performance-based RSUs ("PSUs") that vested 100% on July 15, 2026 after specified performance goals were achieved. The PSUs settled at a reported price of $0.0000 per share, increasing Moran’s direct holdings to 81,601 common shares. The transaction was coded as a grant/award acquisition, not a market purchase or sale, and was not indicated as being under a Rule 10b5-1 trading plan.

Kestra Medical Technologies Chief Commercial Officer Alfred J. Ford Jr. acquired 58,832 Common Shares on July 15, 2026 at $0.00 per share. The shares were earned from performance-based RSUs granted July 17, 2025, which vested 100%, bringing his direct holdings to 133,471 shares.

Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem acquired 44,118 Common Shares on July 15, 2026, at 0.0000 per share, upon vesting of performance-based RSUs granted on July 17, 2025 after achievement of specified goals. Following this award, he directly owns 112,079 Common Shares.

Kestra Medical Technologies, Ltd. reported that director and General Counsel Traci S. Umberger acquired 58,832 Common Shares on July 15, 2026 at $0.00 per share, reflecting the vesting of performance-based RSUs (PSUs) granted on July 17, 2025. After this award, Umberger directly holds 221,634 Common Shares.

Kestra Medical Technologies President and CEO Brian Daniel Webster reported several Common Share transactions dated July 15, 2026. He acquired 176,470 shares at $0.0000 per share upon full vesting of performance-based RSUs granted in 2025, then sold a total of 15,000 shares at weighted-average prices of $22.0105, $22.6333 and $23.9983, with underlying trade prices ranging from $21.45 to $24.10, under a Rule 10b5-1 trading plan adopted September 29, 2025. Following these transactions, he directly owned 556,937 Common Shares.

Kestra Medical Technologies Chief Business Officer Timothy P. Moran acquired additional company stock through an employee purchase plan. He obtained 227 shares of common stock on June 30, 2026 at $21.55 per share under the 2025 Employee Stock Purchase Plan for the January 1–June 30, 2026 period. Following this ESPP purchase, he directly holds 42,488 shares of Kestra Medical Technologies common stock, which the disclosure states includes unvested restricted stock units.

Kestra Medical Technologies director and officer Traci S. Umberger acquired 942 shares of common stock through the company’s Employee Stock Purchase Plan. The shares were purchased for $21.55 per share, equal to 85% of the closing price on June 29, 2026, under a plan exempt under Rule 16b-3.

Following this ESPP purchase for the period from January 1, 2026 through June 30, 2026, Umberger beneficially owns 162,802 shares of Kestra common stock, which the filing notes includes unvested restricted stock units (RSUs).

KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares. The sale was executed at a weighted average price of $20.8095 per share, with individual trade prices ranging from $20.5400 to $21.3900.

After this transaction, Webster directly holds 395,467 common shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.

Moran Timothy P. reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies reported that Chief Business Officer Timothy P. Moran received a grant of 22,704 restricted stock units (RSUs), each representing one common share at settlement. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to his continued service. Following this award, Moran holds 42,261 common shares directly. This is a compensation-related equity grant rather than an open-market stock purchase or sale.

Ford Alfred J Jr reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies Chief Commercial Officer receives equity award. Alfred J. Ford Jr. was granted 25,227 restricted stock units, each representing one common share at settlement and awarded at no cash cost. Subject to continued service, the RSUs will vest over three years, with one-third vesting on each anniversary of June 3, 2026. After this grant, his reported direct holdings total 74,639 common shares or share-equivalent units.

Mahboob Vaseem reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported an equity compensation grant in the form of restricted stock units. He was awarded 25,227 RSUs that each entitle him to receive one common share at settlement. Subject to his continued service, one third of these RSUs will vest on each anniversary of June 3, 2026, over a three-year period. Following this grant, he beneficially owns 67,961 common shares, which include 5,837 common shares received in a prior pro rata distribution from West Affum Holdings, L.P. that was exempt under Rule 16a-9.

Umberger Traci S reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies director and officer Traci S. Umberger received a grant of 25,227 restricted stock units (RSUs). These RSUs entitle her to one common share per unit upon settlement and will vest over three years, with one-third vesting on each anniversary of June 3, 2026, subject to continued service. Following this equity award, her direct holdings increased to 161,860 common shares, reflecting routine stock-based compensation rather than an open-market purchase or sale.

Webster Brian Daniel reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies director and officer Brian Daniel Webster received an equity grant of 75,681 restricted stock units (RSUs), each settling into one common share at no purchase price. These RSUs vest over three years, with one-third vesting on each anniversary of June 3, 2026, contingent on his continued service. Following this grant, Webster is reported as beneficially owning 410,467 common shares, showing his overall equity stake including this new award.

Kestra Medical Technologies director and officer Brian Daniel Webster reported selling a total of 15,000 Common Shares in open-market transactions. The sales occurred on May 15, 2026 at weighted average prices of $21.4635 and $20.5287 per share. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Kestra Medical Technologies director and officer Brian Daniel Webster reported an open-market sale of 15,000 common shares on April 15, 2026 at a weighted average price of $20.0447 per share. The trade was executed under a Rule 10b5-1 trading plan adopted on September 29, 2025, and Webster now holds 349,786 common shares directly.

Kestra Medical Technologies director Raymond W. Cohen bought 10,000 Common Shares of KMTS in an open-market purchase at a weighted average price of $19.98 per share. After this transaction, he directly owns 50,903 Common Shares. The footnote explains the trade prices ranged from $19.82 to $20.02 per share.

KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 Common Shares on March 17, 2026 at a weighted average price of $20.2749 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance rather than timed discretionarily. Following this sale, Webster continues to hold 364,786 Common Shares directly, showing he retains a substantial equity stake in the company.

Reilly Kevin C reported acquisition or exercise transactions in this Form 4 filing.

Kestra Medical Technologies director Kevin C. Reilly received an equity award of 8,300 common shares in the form of restricted stock units. The RSUs were granted at no cash cost and each unit represents one common share. All 8,300 RSUs will vest on September 4, 2026, if he continues serving through that date, at which point he would hold 8,300 vested common shares from this award.

Kestra Medical Technologies director and officer Brian Daniel Webster sold a total of 15,000 Common Shares of KMTS in open-market transactions on February 17, 2026. The sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025.

The transactions were executed in three tranches: 11,635 shares at a weighted average price of $25.3937, 3,272 shares at $26.2947, and 93 shares at $27.1789. After these sales, Webster directly held 379,786 Common Shares.

Kestra Medical Technologies president, chief executive officer and director Brian Daniel Webster reported selling 15,000 common shares of KMTS on January 15, 2026. The sale was coded as an open-market sale and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance. The shares were sold at a weighted average price of $22.8016, with individual sale prices ranging from $22.2800 to $23.1340. After this transaction, Webster beneficially owns 394,786 common shares, held directly.